Skip to main content
    I

    Insulet Corporation (PODD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $145.29
    -7.19 (-4.72%)

    Market Cap: $10.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insulet Corporation (PODD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Insulet (PODD) to earn $6.77 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.30B. Of 26 analysts, 15 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 26 ratings average 2.27, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 58% of the ratings.

    RatingAnalystsShare
    Strong Buy415.4%
    Buy1142.3%
    Hold1142.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    26

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 16.8% and revenue estimates rise 11.8%.

    Fiscal year ending Dec 31, 2026
    $6.77
    EPS consensus, revenue $3.30B
    Fiscal year ending Dec 31, 2027
    $7.91
    EPS consensus, revenue $3.69B
    Next report
    Feb 16, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$6.77$5.91 to $7.0125$3.30B$3.28B to $3.32B25
    Dec 31, 2027$7.91$5.58 to $8.4225$3.69B$3.54B to $3.73B25

    Quarterly Estimates

    The EPS consensus falls from $1.81 for the quarter ending Dec 31, 2026 to $1.66 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.81$1.57 to $2.0827$919.43M$858.28M to $985.95M26
    Mar 31, 2027$1.66$1.40 to $1.7817$851.33M$827.00M to $878.50M17

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 8 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202622
    Fiscal year ending Dec 31, 202715
    Quarter ending Mar 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.2% from $6.50.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$6.77$6.51$6.51$6.50$6.50+4.1%
    Fiscal year ending Dec 31, 2027$7.91$7.72$7.73$7.71$7.72+2.4%
    Quarter ending Mar 31, 2027$1.66$1.63$1.64$1.62$1.63+1.8%

    Frequently Asked Questions About PODD

    What is the PODD stock forecast?

    Consensus analyst estimates put Insulet's EPS at $6.77 for the fiscal year ending Dec 31, 2026, on revenue of $3.30B. The consensus rating from 26 analysts is Buy.

    How do analysts rate PODD stock?

    Of 26 analysts covering Insulet, 4 rate it Strong Buy, 11 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PODD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $6.77, with estimates from $5.91 to $7.01 from 25 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $7.91, with estimates from $5.58 to $8.42 from 25 analysts.

    What revenue do analysts expect from Insulet next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.30B, with estimates from $3.28B to $3.32B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.69B, with estimates from $3.54B to $3.73B.

    How many analysts cover PODD?

    26 analysts rate Insulet stock, and 25 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.